CINXE.COM

<!DOCTYPE html> <html class="no-js" lang="en" prefix="og: https://ogp.me/ns#"> <head> <script src="https://sp-library.prod.sp.aws.clarivate.net/oti/latest/index.umd.js"></script> <link href="https://www.bioworld.com/authors/3-jennifer-boggs" rel="canonical"> <meta charset="utf-8"> <meta name="csrf-param" content="authenticity_token" /> <meta name="csrf-token" content="bpBZBj9UZNytGZb85eDlH0lEOpPZnWXq0O4Pziwf6dpxMJuyp9W3nQScFxfVHjQf7eMbihpfE2RJv+MwcJ2Yvg==" /> <meta name="viewport" content="width=device-width, initial-scale=1.0"> <meta name="timestamp" value="2025-02-19 22:45:23 -0500"> <meta name="description" content="BioWorld - Jennifer Boggs" /> <meta name="keywords" content="Jennifer Boggs" /> <link rel="alternate" type="application/xml" title="BioWorld RSS Feed" href="https://www.bioworld.com/rss/articles" /> <meta property="og:title" content="Jennifer Boggs" /> <meta property="og:description" content="Jennifer Boggs" /> <meta property="og:url" content="https://www.bioworld.com/authors/3-jennifer-boggs" /> <meta property="og:type" content="Author" /> <meta name="twitter:title" content="Jennifer Boggs" /> <meta name="twitter:description" content="Jennifer Boggs" /> <meta name="twitter:card" content="summary" /> <meta property="og:title" /> <meta property="og:description" /> <meta property="og:url" /> <meta property="og:type" content="Website" /> <meta content="false" name="has-log-view" /> <title>Jennifer Boggs | BioWorld</title> <link rel="stylesheet" media="screen" href="/stylesheets/application.css?v=1740023123" /> <script src="/javascripts/jade.default.min.js?v=1740023123"></script> <script src="/javascripts/application.js?v=1740023123"></script>  <script>var dataLayer = window.dataLayer || [];</script> <script>let snowplowData = {"event":"SnowplowStructuredEvent","product":""}; fetch('/user/snowplow', { method: 'GET', headers: { 'Content-Type': 'application/json' } }) .then(response => { if (!response.ok) { throw new Error(`HTTP error! status: ${response.status}`); } return response.json(); }) .then(data => { const evt = Object.assign({}, snowplowData, data); console.info('Snowplow Data:', evt); // Handle the fetched data dataLayer.push(evt); }) .catch(error => { console.error('Error fetching snowplow data:', error); // Handle any errors });</script><script>dataLayer.push({"id":3,"title":"Jennifer Boggs","page_type":["authors"],"date_posted":"07/19/2019","gated":false,"registered":false});</script> <script>typeof window.dataLayer[0] === 'object' && !('page_type' in window.dataLayer[0]) && window.dataLayer.push({"id":3,"title":"Jennifer Boggs","page_type":["authors"],"date_posted":"07/19/2019","gated":false,"registered":false});</script>   <script> //<![CDATA[ (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= '//www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-5ZV86V9'); //]]> </script>  <script> window.epub = window.epub || {}; window.epub['AD_HISTORY_ENABLED'] = false; </script> <link rel="apple-touch-icon" sizes="180x180" href="/icons/apple-touch-icon.png"> <link rel="icon" type="image/png" sizes="32x32" href="/icons/favicon-32x32.png"> <link rel="icon" type="image/png" sizes="16x16" href="/icons/favicon-16x16.png"> <link rel="manifest" href="/icons/site.webmanifest"> <link rel="mask-icon" href="/icons/safari-pinned-tab.svg" color="#5bbad5"> <link rel="shortcut icon" href="/icons/favicon.ico"> <meta name="msapplication-TileColor" content="#00aba9"> <meta name="msapplication-config" content="/icons/browserconfig.xml"> <meta name="theme-color" content="#ffffff"><script> var googletag = { cmd: [] }; var targeting = window.targeting = {"id":"3","tags":[],"taxonomy":[],"taxonomy_id":[],"sponsored":"false","page_type":["authors"],"keyword":[],"reg_user":"false","page_name":"3-jennifer-boggs","search_terms":"","url":"/authors/3-jennifer-boggs","site_env":"production"}; </script> <script> (function(ac) { var d = document, s = 'script', id = 'adplugg-adjs'; var js, fjs = d.getElementsByTagName(s)[0]; if (d.getElementById(id)) return; js = d.createElement(s); js.id = id; js.async = 1; js.src = '//www.adplugg.com/serve/' + ac + '/js/1.1/ad.js'; fjs.parentNode.insertBefore(js, fjs); }('A48225833')); </script><script>if (typeof Oti !== "undefined" && typeof Oti.OtiService !== "undefined") { $.post('/user/pendo', function(data) { const pendoVisitor = data.visitor const pendoAccount = Object.keys(pendoVisitor).length > 0 ? data.account : '' const anomID = localStorage.getItem('anomID') || (localStorage.setItem('anomID', `${navigator.userAgent}-${screen.width}x${screen.height}-${navigator.language}`.split('').reduce((hash, char) => ((hash << 5) - hash) + char.charCodeAt(0), 0).toString(36)) || localStorage.getItem('anomID')) const pendovistorID = (pendoVisitor && Object.keys(pendoVisitor).length > 0 && pendoVisitor.id) ? `${pendoVisitor.id}` : anomID; const otiService = new Oti.OtiService({ ot_key: "603e2c5b-3a1d-4eac-a9c9-fb20c3b528f2", prod_domain: "www.bioworld.com", pendo_key: "34b78be2-b210-4df9-7f2b-7552afe5341c", pendo_details: { visitor: { id: pendovistorID, firstName: pendoVisitor.first_name, lastName: pendoVisitor.last_name, email: pendoVisitor.email, country: pendoVisitor.country, company: pendoVisitor.company, last_login: pendoVisitor.last_login, opted_out_at: pendoVisitor.opted_out_at, }, account: { id: pendoAccount } }, pendo_visitor_payload: [{ visitorId: pendovistorID, values: { firstName: pendoVisitor.first_name, lastName: pendoVisitor.last_name, email: pendoVisitor.email, country: pendoVisitor.country, company: pendoVisitor.company, last_login: pendoVisitor.last_login, opted_out_at: pendoVisitor.opted_out_at, } }], pendo_visitor_url: '/ui/pendoapi/agent/value?create=true', pendo_dnp_url: `/ui/pendoapi/pendo/value/${pendovistorID}/donotprocess`, pendo_metadata_url: `/ui/pendoapi/custom/value/${pendovistorID}/bioworld_targetingcookies`, }); otiService.initialize(); }); }</script> <link rel="preload" as="script" href="https://cdn.ampproject.org/v0.js"> <script async src="https://cdn.ampproject.org/v0.js"></script>  <style amp-custom>/* Add your styles here */</style> <style amp-boilerplate>body{-webkit-animation:-amp-start 8s steps(1,end) 0s 1 normal both;-moz-animation:-amp-start 8s steps(1,end) 0s 1 normal both;-ms-animation:-amp-start 8s steps(1,end) 0s 1 normal both;animation:-amp-start 8s steps(1,end) 0s 1 normal both}@-webkit-keyframes -amp-start{from{visibility:hidden}to{visibility:visible}}@-moz-keyframes -amp-start{from{visibility:hidden}to{visibility:visible}}@-ms-keyframes -amp-start{from{visibility:hidden}to{visibility:visible}}@-o-keyframes -amp-start{from{visibility:hidden}to{visibility:visible}}@keyframes -amp-start{from{visibility:hidden}to{visibility:visible}}</style><noscript><style amp-boilerplate>body{-webkit-animation:none;-moz-animation:none;-ms-animation:none;animation:none}</style></noscript> <link rel="canonical" href="."> <script async custom-element="amp-iframe" src="https://cdn.ampproject.org/v0/amp-iframe-0.1.js"></script> <script>var _document$querySelect, _document$querySelect2; var $hasLogViewMeta = (_document$querySelect = document.querySelector('meta[name=has-log-view]')) === null || _document$querySelect === void 0 ? void 0 : _document$querySelect.getAttribute('content'); var $logViewUrlMeta = (_document$querySelect2 = document.querySelector('meta[name=log-view-url]')) === null || _document$querySelect2 === void 0 ? void 0 : _document$querySelect2.getAttribute('content'); if ($hasLogViewMeta === 'true') { var baseLogUrl = (typeof $logViewUrlMeta === "undefined" ? window.location.pathname : $logViewUrlMeta).replace(/(\d+)-.*$/, '$1'); var logUrl = baseLogUrl + '/log_view' + window.location.search; if (typeof navigator.sendBeacon === 'function') { navigator.sendBeacon(logUrl); } else { // Gotta love IE var request = new XMLHttpRequest(); request.open('POST', logUrl, true); request.setRequestHeader('Content-Type', 'application/x-www-form-urlencoded; charset=UTF-8'); request.send(); } }</script> </head> <body data-controller="authors" data-action="show" data-prestitial-ad="false" data-poststitial-ad="false" data-news-services="">  <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-5ZV86V9" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>  <div class="document mmenu-placeholder"><header class="main-header"><div class="main-header__top"><h1> <a href="/" class="main-header__logo" data-eventaction="logo-link" data-eventcategory="click" data-eventlabel="link to homepage" data-eventname="logo-link"> <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 201 36" height="36" fill="none" preservAspectRatio="xMidYMid meet"> <title>BioWorld. Link to homepage.</title> <path fill="#000" d="M17.7999 16.5745v.1066c3.8891 1.5805 6.2511 4.4219 6.2511 8.3111 0 5.3809-3.9958 9.6608-11.0993 9.6608H1V1.01776h10.8506c6.9082 0 10.3712 4.27988 10.3712 8.59527 0 2.93017-1.4385 5.57627-4.4219 6.96147zM7.67732 6.68283v7.49427H11.087c2.3975 0 4.3687-1.2076 4.3687-3.8004 0-2.59283-2.06-3.69387-4.3687-3.69387H7.67732zm0 22.34057h3.46298c4.0313 0 5.9492-1.8646 5.9492-4.6173 0-2.8414-2.3619-4.2798-5.6118-4.2798H7.67732v8.8971zM35.239 34.6352h-6.2333v-16.711h-3.0723V12.632h9.3056v22.0032zM31.8293 1.01776c2.2554 0 4.0313 1.82916 4.0313 4.03125 0 2.25538-1.7759 3.97798-4.0313 3.97798-2.2021 0-3.9957-1.7226-3.9957-3.97798.0178-2.20209 1.7936-4.03125 3.9957-4.03125zM39.217 23.6425c0-6.7128 5.2389-11.5787 11.7564-11.5787 6.5175 0 11.7563 4.8481 11.7563 11.5787s-5.2388 11.5788-11.7563 11.5788c-6.5175 0-11.7564-4.8659-11.7564-11.5788zm6.2511 0c0 3.4097 2.2554 6.0025 5.523 6.0025 3.2144 0 5.4697-2.5928 5.4697-6.0025 0-3.463-2.2553-6.0025-5.4697-6.0025-3.2676 0-5.523 2.5395-5.523 6.0025zM88.7286 1.01776L95.1573 25.081h.0533l5.3814-24.06324h6.819L99.2064 34.6352h-7.7251l-6.3399-24.152-6.1979 24.152h-7.7251L62.9073 1.01776h7.2101L75.303 25.081h.0532l6.4287-24.06324h6.9437zM106.701 23.6425c0-6.7128 5.238-11.5787 11.756-11.5787 6.535 0 11.756 4.8481 11.756 11.5787s-5.239 11.5788-11.756 11.5788c-6.535-.0178-11.756-4.8659-11.756-11.5788zm6.233 0c0 3.4097 2.255 6.0025 5.523 6.0025 3.214 0 5.47-2.5928 5.47-6.0025 0-3.463-2.256-6.0025-5.47-6.0025-3.268 0-5.523 2.5395-5.523 6.0025zm34.772-4.8481h-2.646c-3.161 0-4.618 1.4917-4.618 5.3276v10.5132h-6.233V12.632h6.056v3.4985c.87-2.3441 2.983-3.8004 5.718-3.8004.586 0 1.154.0533 1.723.1954v6.2689zm9.696 15.8408h-6.198V1.01776h6.198V34.6352zm21.559-2.7881c-1.101 1.8292-3.694 3.3564-6.872 3.3564-6.056 0-10.656-4.8481-10.656-11.5787s4.564-11.5788 10.62-11.5788c3.357 0 5.914 1.545 7.015 3.4097 0-.7281-.089-2.5395-.089-4.1733V1h6.233v33.6175h-6.233v-2.7704h-.018zm-11.081-8.2046c0 3.3564 2.308 6.0558 5.612 6.0558 3.303 0 5.611-2.6994 5.611-6.0558 0-3.4097-2.308-6.0025-5.611-6.0025-3.304 0-5.612 2.5928-5.612 6.0025zM191.801 2.58054h2.06V1.01776h-5.772v1.56278h2.043V6.8249h1.669V2.58054zM201 6.8249V1.01776h-2.184l-1.119 2.84141-1.101-2.84141h-2.22V6.8249h1.652V3.13106l1.101 2.66382h1.065l1.101-2.68158v3.7116H201z"/> </svg> </a> </h1><a href='https://clarivate.com/cortellis/' target="_blank" class="main-header__logo -clarivate"> <img src="/images/Cortellis_Flagship_Logo.png" alt="Clarivate" title="Powering insights from Cortellis. Link to Cortellis page on Clarivate website."> </a></div><div class="main-nav-container"><div class="main-nav-container__wrapper"><nav id="main-nav" class="main-nav main-nav--horizontal"><div class="navigation"><ul class="main-nav-level1__items"><li class="main-nav-level1__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="BioWorld|/topics/84-bioworld" href="/topics/84-bioworld">BioWorld</a></li><li class="main-nav-level1__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="BioWorld MedTech|/topics/85-bioworld-medtech" href="/topics/85-bioworld-medtech">BioWorld MedTech</a></li><li class="main-nav-level1__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="BioWorld Asia|/topics/86-bioworld-asia" href="/topics/86-bioworld-asia">BioWorld Asia</a></li><li class="main-nav-level1__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="BioWorld Science|/topics/520-bioworld-science" href="/topics/520-bioworld-science">BioWorld Science</a></li><li class="main-nav-level1__item"><a class="main-nav__link -has-children" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Data Snapshots|/snapshots" href="/snapshots">Data Snapshots</a><ul class="main-nav-level2__items"><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="BioWorld|/snapshots" href="/snapshots">BioWorld</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="BioWorld MedTech|/medtech_snapshots" href="/medtech_snapshots">BioWorld MedTech</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Infographics: Dynamic digital data analysis|/infographics-index" href="/infographics-index">Infographics: Dynamic digital data analysis</a></li></ul></li><li class="main-nav-level1__item"><a class="main-nav__link -has-children" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Special reports|/special_reports" href="/special_reports">Special reports</a><ul class="main-nav-level2__items"><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Infographics: Dynamic digital data analysis|/infographics-index" href="/infographics-index">Infographics: Dynamic digital data analysis</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Trump administration impacts|/Trump_administration_impacts" href="/Trump_administration_impacts">Trump administration impacts</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Biopharma M&A scorecard|/biopharma_MandA_scorecard" href="/biopharma_MandA_scorecard">Biopharma M&A scorecard</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="BioWorld 2024 review|/BioWorld_2024_review" href="/BioWorld_2024_review">BioWorld 2024 review</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="BioWorld MedTech 2024 review|https://www.bioworld.com/medtech_trends_2024" href="https://www.bioworld.com/medtech_trends_2024">BioWorld MedTech 2024 review</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="BioWorld Science 2024 review|/BioWorld_Science_2024_review" href="/BioWorld_Science_2024_review">BioWorld Science 2024 review</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Women's health|/womens_health" href="/womens_health">Women's health</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="China's GLP-1 landscape|/China_GLP-1" href="/China_GLP-1">China's GLP-1 landscape</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="PFA re-energizes afib market|https://www.bioworld.com/articles/711618-pulsed-field-ablation-re-energizes-the-atrial-fibrillation-market" href="https://www.bioworld.com/articles/711618-pulsed-field-ablation-re-energizes-the-atrial-fibrillation-market">PFA re-energizes afib market</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="China CAR T|/China_CAR_T" href="/China_CAR_T">China CAR T</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Alzheimer's disease|/Alzheimers" href="/Alzheimers">Alzheimer's disease</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Israel|/israel" href="/israel">Israel</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Rise of obesity|/rise_of_obesity" href="/rise_of_obesity">Rise of obesity</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Radiopharmaceuticals|/radiopharmaceuticals" href="/radiopharmaceuticals">Radiopharmaceuticals</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Biosimilars|/biosimilars" href="/biosimilars">Biosimilars</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Aging|/aging" href="/aging">Aging</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="IVDs on the rise|/IVDs-2021" href="/IVDs-2021">IVDs on the rise</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Coronavirus|/articles/topic/517" href="/articles/topic/517">Coronavirus</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Artificial intelligence|/AI_series" href="/AI_series">Artificial intelligence</a></li></ul></li></ul></div></nav><div class="main-nav-container__mobile-nav"><a class="hamburger-nav-link" href="#" id="hamburger-nav-link"></a><h1> <a href="/" class="main-header__logo" data-eventaction="logo-link" data-eventcategory="click" data-eventlabel="link to homepage" data-eventname="logo-link"> <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 201 36" height="36" fill="none" preservAspectRatio="xMidYMid meet"> <title>BioWorld. Link to homepage.</title> <path fill="#000" d="M17.7999 16.5745v.1066c3.8891 1.5805 6.2511 4.4219 6.2511 8.3111 0 5.3809-3.9958 9.6608-11.0993 9.6608H1V1.01776h10.8506c6.9082 0 10.3712 4.27988 10.3712 8.59527 0 2.93017-1.4385 5.57627-4.4219 6.96147zM7.67732 6.68283v7.49427H11.087c2.3975 0 4.3687-1.2076 4.3687-3.8004 0-2.59283-2.06-3.69387-4.3687-3.69387H7.67732zm0 22.34057h3.46298c4.0313 0 5.9492-1.8646 5.9492-4.6173 0-2.8414-2.3619-4.2798-5.6118-4.2798H7.67732v8.8971zM35.239 34.6352h-6.2333v-16.711h-3.0723V12.632h9.3056v22.0032zM31.8293 1.01776c2.2554 0 4.0313 1.82916 4.0313 4.03125 0 2.25538-1.7759 3.97798-4.0313 3.97798-2.2021 0-3.9957-1.7226-3.9957-3.97798.0178-2.20209 1.7936-4.03125 3.9957-4.03125zM39.217 23.6425c0-6.7128 5.2389-11.5787 11.7564-11.5787 6.5175 0 11.7563 4.8481 11.7563 11.5787s-5.2388 11.5788-11.7563 11.5788c-6.5175 0-11.7564-4.8659-11.7564-11.5788zm6.2511 0c0 3.4097 2.2554 6.0025 5.523 6.0025 3.2144 0 5.4697-2.5928 5.4697-6.0025 0-3.463-2.2553-6.0025-5.4697-6.0025-3.2676 0-5.523 2.5395-5.523 6.0025zM88.7286 1.01776L95.1573 25.081h.0533l5.3814-24.06324h6.819L99.2064 34.6352h-7.7251l-6.3399-24.152-6.1979 24.152h-7.7251L62.9073 1.01776h7.2101L75.303 25.081h.0532l6.4287-24.06324h6.9437zM106.701 23.6425c0-6.7128 5.238-11.5787 11.756-11.5787 6.535 0 11.756 4.8481 11.756 11.5787s-5.239 11.5788-11.756 11.5788c-6.535-.0178-11.756-4.8659-11.756-11.5788zm6.233 0c0 3.4097 2.255 6.0025 5.523 6.0025 3.214 0 5.47-2.5928 5.47-6.0025 0-3.463-2.256-6.0025-5.47-6.0025-3.268 0-5.523 2.5395-5.523 6.0025zm34.772-4.8481h-2.646c-3.161 0-4.618 1.4917-4.618 5.3276v10.5132h-6.233V12.632h6.056v3.4985c.87-2.3441 2.983-3.8004 5.718-3.8004.586 0 1.154.0533 1.723.1954v6.2689zm9.696 15.8408h-6.198V1.01776h6.198V34.6352zm21.559-2.7881c-1.101 1.8292-3.694 3.3564-6.872 3.3564-6.056 0-10.656-4.8481-10.656-11.5787s4.564-11.5788 10.62-11.5788c3.357 0 5.914 1.545 7.015 3.4097 0-.7281-.089-2.5395-.089-4.1733V1h6.233v33.6175h-6.233v-2.7704h-.018zm-11.081-8.2046c0 3.3564 2.308 6.0558 5.612 6.0558 3.303 0 5.611-2.6994 5.611-6.0558 0-3.4097-2.308-6.0025-5.611-6.0025-3.304 0-5.612 2.5928-5.612 6.0025zM191.801 2.58054h2.06V1.01776h-5.772v1.56278h2.043V6.8249h1.669V2.58054zM201 6.8249V1.01776h-2.184l-1.119 2.84141-1.101-2.84141h-2.22V6.8249h1.652V3.13106l1.101 2.66382h1.065l1.101-2.68158v3.7116H201z"/> </svg> </a> </h1><a class="search-nav-link" href="#" id="search-nav-link"></a><form action="/search" class="mobile-search" id="mobile-search" method="get"><input class="mobile-search__field" name="q" placeholder="What are you looking for?" type="text" /><button class="mobile-search__icon" type="submit"></button></form></div><div class="main-nav-container__nav2"><nav class="user-actions" id="user-actions"> <ul class="user-actions__list"> <li class="user-actions__signin"> <a class="user-actions__signin-link" href="/user/login">Sign In</a> </li> <li class="user-actions__signout"> <a class="user-actions__signout-link" href="/user/logout">Sign Out</a> </li> <li class="user-actions__account"> <a class="user-actions__account-link" href="/user/profile">My Account</a> </li> </ul> </nav> <a class="main-nav-container__subscribe-link" href="/subscriptions">Subscribe</a><div class="quick-search" id="quick-search"><form action="/search" id="quick-search-form" method="GET" name="quick-search" target="_top"><div class="quick-search__wrapper" role="presentation"><input class="quick-search__search-field" id="q" name="q" placeholder="Search" type="text" /><button class="quick-search__button" title="Search" type="submit"></button></div></form></div></div></div></div></header><div class="container"><section class="site-banner" id="site-banner"><div class="site-banner__date">BioWorld - Wednesday, February 19, 2025</div></section><div id="section-2" class="author-show main-body page-authors-show"> <div id="breadcrumbs" class="breadcrumbs"><a class="" href="/">Home</a> » <a class="" href="https://www.bioworld.com/authors">Authors</a> » Jennifer Boggs</div> <div class="author-bio"> <div class="detail "> <h1 class="headline author-name"><a href="https://www.bioworld.com/authors/3-jennifer-boggs">Jennifer Boggs</a></h1> <div class="abstract"></div> <div class="link position"> </div> <div class="link articles"> <a href="https://www.bioworld.com/authors/3-jennifer-boggs/articles">Articles</a> </div> </div> </div> <div class="author-tab-list box1"><div class="records articles-list"> <h3 class="feature-title articles-list__title">ARTICLES</h3> <div class="articles-list__row"> <article class="record article-summary "> <div class="article-summary__details "> <h2 class="headline article-summary__headline"><a href="https://www.bioworld.com/articles/717262-uncharted-territory-for-pliant-after-ipf-trial-pause">Uncharted territory’ for Pliant after IPF trial pause</a></h2> <div class="post-meta"> <div class="date article-summary__post-date">Feb. 13, 2025</div> <div class="author article-summary__author">By <a href="/authors/3-jennifer-boggs">Jennifer Boggs</a></div> <div class="comment-count article-summary__comment-count"><a title="Uncharted territory’ for Pliant after IPF trial pause" class="more" href="https://www.bioworld.com/articles/717262-uncharted-territory-for-pliant-after-ipf-trial-pause#comments-container">No Comments</a></div> </div> <div class="abstract article-summary__teaser">Pliant Therapeutics Inc., which offered few details earlier this week when it voluntarily paused enrollment in the phase IIb Beacon-IPF trial testing bexotegrast in idiopathic pulmonary fibrosis (IPF), has taken an unusual step as it assembles a panel of outside experts to review unblinded data from the study with the goal of providing an independent recommendation.<br /></div><a title="Uncharted territory’ for Pliant after IPF trial pause" class="more" href="https://www.bioworld.com/articles/717262-uncharted-territory-for-pliant-after-ipf-trial-pause">Read More</a> </div> </article> <article class="record article-summary "> <div class="image"><a title="Springworks’ Gomekli wins priority FDA nod for NF1 neurofibromas" class="url" rel="" target="" href="https://www.bioworld.com/articles/717351-springworks-gomekli-wins-priority-fda-nod-for-nf1-neurofibromas"><img width="731" height="488" alt="Gomekli packaging" title="Gomekli packaging" border="0" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Gomekli-packaging.jpg?height=488&t=1739392383&width=650" /></a></div> <div class="article-summary__details has-image"> <h2 class="headline article-summary__headline"><a href="https://www.bioworld.com/articles/717351-springworks-gomekli-wins-priority-fda-nod-for-nf1-neurofibromas">Springworks’ Gomekli wins priority FDA nod for NF1 neurofibromas</a></h2> <div class="post-meta"> <div class="date article-summary__post-date">Feb. 12, 2025</div> <div class="author article-summary__author">By <a href="/authors/3-jennifer-boggs">Jennifer Boggs</a></div> </div> <div class="abstract article-summary__teaser">Snagging its second U.S. FDA approval since being spun out of Pfizer Inc. in 2017, Springworks Therapeutics Inc. is aiming to position Gomekli (mirdametinib), cleared for neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN) not amenable to complete resection, as a first-in-class drug for adults and potentially best-in-class option for children. The priority approval, which came after market close Feb. 11, more than two weeks ahead of the Feb. 28 PDUFA date, marks the second MEK1/2 inhibitor to hit the market for NF1-PN, a rare, genetic condition.<br /></div><a title="Springworks’ Gomekli wins priority FDA nod for NF1 neurofibromas" class="more" href="https://www.bioworld.com/articles/717351-springworks-gomekli-wins-priority-fda-nod-for-nf1-neurofibromas">Read More</a> </div> </article> <article class="record article-summary "> <div class="image"><a title="Qlaris’ QLS-111 reduces eye pressure in two phase II trials" class="url" rel="" target="" href="https://www.bioworld.com/articles/716975-qlaris-qls-111-reduces-eye-pressure-in-two-phase-ii-trials"><img width="650" height="488" alt="Close up of man's eye" title="Close up of man's eye" border="0" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Ocular-eye-analysis.png?height=488&t=1682533522&width=650" /></a></div> <div class="article-summary__details has-image"> <h2 class="headline article-summary__headline"><a href="https://www.bioworld.com/articles/716975-qlaris-qls-111-reduces-eye-pressure-in-two-phase-ii-trials">Qlaris’ QLS-111 reduces eye pressure in two phase II trials</a></h2> <div class="post-meta"> <div class="date article-summary__post-date">Feb. 5, 2025</div> <div class="author article-summary__author">By <a href="/authors/3-jennifer-boggs">Jennifer Boggs</a></div> <div class="comment-count article-summary__comment-count"><a title="Qlaris’ QLS-111 reduces eye pressure in two phase II trials" class="more" href="https://www.bioworld.com/articles/716975-qlaris-qls-111-reduces-eye-pressure-in-two-phase-ii-trials#comments-container">No Comments</a></div> </div> <div class="abstract article-summary__teaser">Touting its novel approach for treating glaucoma, Qlaris Bio Inc. reported promising top-line data from two phase II studies testing QLS-111 in patients with primary open-angle glaucoma and ocular hypertension, showing the drug met all primary and secondary endpoints, reducing intraocular pressure with a clean safety profile that could encourage patients to remain on treatment.<br /></div><a title="Qlaris’ QLS-111 reduces eye pressure in two phase II trials" class="more" href="https://www.bioworld.com/articles/716975-qlaris-qls-111-reduces-eye-pressure-in-two-phase-ii-trials">Read More</a> </div> </article> <article class="record article-summary "> <div class="image"><a title="Vertex wins FDA nod for Journavx, new mechanism for acute pain" class="url" rel="" target="" href="https://www.bioworld.com/articles/716969-vertex-wins-fda-nod-for-journavx-new-mechanism-for-acute-pain"><img width="650" height="488" alt="Journavx bottle and tablet " title="Journavx bottle and tablet " border="0" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Journavx-bottle-and-tablet-.jpg?height=488&t=1738340382&width=650" /></a></div> <div class="article-summary__details has-image"> <h2 class="headline article-summary__headline"><a href="https://www.bioworld.com/articles/716969-vertex-wins-fda-nod-for-journavx-new-mechanism-for-acute-pain">Vertex wins FDA nod for Journavx, new mechanism for acute pain</a></h2> <div class="post-meta"> <div class="date article-summary__post-date">Jan. 31, 2025</div> <div class="author article-summary__author">By <a href="/authors/3-jennifer-boggs">Jennifer Boggs</a></div> </div> <div class="abstract article-summary__teaser">An effort two decades in the making, Vertex Pharmaceuticals Inc.’s suzetrigine gained U.S. FDA approval as the first drug targeting the NaV1.8 pain signal. Branded Journavx, the oral small molecule is cleared for use as a non-opioid option for treating moderate to severe acute pain.<br /></div><a title="Vertex wins FDA nod for Journavx, new mechanism for acute pain" class="more" href="https://www.bioworld.com/articles/716969-vertex-wins-fda-nod-for-journavx-new-mechanism-for-acute-pain">Read More</a> </div> </article> <article class="record article-summary "> <div class="image"><a title="Regulus heads to phase III after more positive kidney disease data" class="url" rel="" target="" href="https://www.bioworld.com/articles/716735-regulus-heads-to-phase-iii-after-more-positive-kidney-disease-data"><img width="650" height="488" alt="Illustration of polycystic kidney" title="Illustration of polycystic kidney" border="0" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Nephrology/polycystic-kidney-disease.jpg?height=488&t=1711123698&width=650" /></a></div> <div class="article-summary__details has-image"> <h2 class="headline article-summary__headline"><a href="https://www.bioworld.com/articles/716735-regulus-heads-to-phase-iii-after-more-positive-kidney-disease-data">Regulus heads to phase III after more positive kidney disease data</a></h2> <div class="post-meta"> <div class="date article-summary__post-date">Jan. 29, 2025</div> <div class="author article-summary__author">By <a href="/authors/3-jennifer-boggs">Jennifer Boggs</a></div> <div class="comment-count article-summary__comment-count"><a title="Regulus heads to phase III after more positive kidney disease data" class="more" href="https://www.bioworld.com/articles/716735-regulus-heads-to-phase-iii-after-more-positive-kidney-disease-data#comments-container">No Comments</a></div> </div> <div class="abstract article-summary__teaser">In an indication that has proved difficult for biopharma to conquer, Regulus Therapeutics Inc. disclosed further positive data from its ongoing phase Ib study testing RGLS-8429 in autosomal dominant polycystic kidney disease and laid out its plans to move straight into a phase III trial later this year, with the potential for an accelerated U.S. approval.<br /></div><a title="Regulus heads to phase III after more positive kidney disease data" class="more" href="https://www.bioworld.com/articles/716735-regulus-heads-to-phase-iii-after-more-positive-kidney-disease-data">Read More</a> </div> </article> <article class="record article-summary "> <div class="image"><a title="Akero’s EFX reverses cirrhosis in MASH patients in phase IIb trial" class="url" rel="" target="" href="https://www.bioworld.com/articles/716628-akeros-efx-reverses-cirrhosis-in-mash-patients-in-phase-iib-trial"><img width="650" height="488" alt="Liver over digital lens background" title="Liver over digital lens background" border="0" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Liver-on-digital-lens.jpg?height=488&t=1709588066&width=650" /></a></div> <div class="article-summary__details has-image"> <h2 class="headline article-summary__headline"><a href="https://www.bioworld.com/articles/716628-akeros-efx-reverses-cirrhosis-in-mash-patients-in-phase-iib-trial">Akero’s EFX reverses cirrhosis in MASH patients in phase IIb trial</a></h2> <div class="post-meta"> <div class="date article-summary__post-date">Jan. 27, 2025</div> <div class="author article-summary__author">By <a href="/authors/3-jennifer-boggs">Jennifer Boggs</a></div> <div class="comment-count article-summary__comment-count"><a title="Akero’s EFX reverses cirrhosis in MASH patients in phase IIb trial" class="more" href="https://www.bioworld.com/articles/716628-akeros-efx-reverses-cirrhosis-in-mash-patients-in-phase-iib-trial#comments-container">No Comments</a></div> </div> <div class="abstract article-summary__teaser">What a difference 60 weeks can make. That’s the lesson Akero Therapeutics Inc. shared with the rollout of what executives called “unprecedented” data from the phase IIb Symmetry trial testing efruxifermin (EFX), its FGF21 receptor agonist, in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH). While earlier findings had shown only a trend in improvement at 36 weeks, full 96-week results showed more than doubling of earlier effect size, hitting the primary endpoint and sending shares of Akero (NASDAQ:AKRO) up 97% to close Jan. 27 at $51.71.<br /></div><a title="Akero’s EFX reverses cirrhosis in MASH patients in phase IIb trial" class="more" href="https://www.bioworld.com/articles/716628-akeros-efx-reverses-cirrhosis-in-mash-patients-in-phase-iib-trial">Read More</a> </div> </article> <article class="record article-summary "> <div class="image"><a title="FDA clears Medexus’ HSCT conditioning agent treosulfan – finally" class="url" rel="" target="" href="https://www.bioworld.com/articles/716607-fda-clears-medexus-hsct-conditioning-agent-treosulfan-finally"><img width="650" height="488" alt="FDA approved icons and medical professional" title="FDA approved icons and medical professional" border="0" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/FDA-approved-icons-and-medical-professional.png?height=488&t=1639686678&width=650" /></a></div> <div class="article-summary__details has-image"> <h2 class="headline article-summary__headline"><a href="https://www.bioworld.com/articles/716607-fda-clears-medexus-hsct-conditioning-agent-treosulfan-finally">FDA clears Medexus’ HSCT conditioning agent treosulfan – finally</a></h2> <div class="post-meta"> <div class="date article-summary__post-date">Jan. 22, 2025</div> <div class="author article-summary__author">By <a href="/authors/3-jennifer-boggs">Jennifer Boggs</a></div> <div class="comment-count article-summary__comment-count"><a title="FDA clears Medexus’ HSCT conditioning agent treosulfan – finally" class="more" href="https://www.bioworld.com/articles/716607-fda-clears-medexus-hsct-conditioning-agent-treosulfan-finally#comments-container">No Comments</a></div> </div> <div class="abstract article-summary__teaser">Medexus Pharmaceuticals Inc. looks set for its U.S. launch of bifunctional alkylating agent treosulfan in the first half of 2025 following a long-awaited FDA approval of the drug, branded Grafapex, for use in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adults and pediatric patients, 1 and older, with acute myeloid leukemia or myelodysplastic syndrome. <br /></div><a title="FDA clears Medexus’ HSCT conditioning agent treosulfan – finally" class="more" href="https://www.bioworld.com/articles/716607-fda-clears-medexus-hsct-conditioning-agent-treosulfan-finally">Read More</a> </div> </article> <article class="record article-summary "> <div class="image"><a title="OS Therapies heading to FDA with positive osteosarcoma data" class="url" rel="" target="" href="https://www.bioworld.com/articles/716293-os-therapies-heading-to-fda-with-positive-osteosarcoma-data"><img width="650" height="488" alt="Illustration of knee joint, giant cell tumor of bone" title="Illustration of knee joint, giant cell tumor of bone" border="0" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Knee-joint-giant-cell-tumor-of-bone.jpg?height=488&t=1731436821&width=650" /></a></div> <div class="article-summary__details has-image"> <h2 class="headline article-summary__headline"><a href="https://www.bioworld.com/articles/716293-os-therapies-heading-to-fda-with-positive-osteosarcoma-data">OS Therapies heading to FDA with positive osteosarcoma data</a></h2> <div class="post-meta"> <div class="date article-summary__post-date">Jan. 15, 2025</div> <div class="author article-summary__author">By <a href="/authors/3-jennifer-boggs">Jennifer Boggs</a></div> <div class="comment-count article-summary__comment-count"><a title="OS Therapies heading to FDA with positive osteosarcoma data" class="more" href="https://www.bioworld.com/articles/716293-os-therapies-heading-to-fda-with-positive-osteosarcoma-data#comments-container">No Comments</a></div> </div> <div class="abstract article-summary__teaser">With positive data in hand from its phase IIb trial testing immunotherapy candidate OST-HER2 in osteosarcoma, OS Therapies Inc. anticipates a regulatory filing this year seeking accelerated approval from the U.S. FDA, putting the firm on track to receive a potentially profitable rare pediatric disease priority review voucher that could help fund further R&D work. Should OST-HER2 go on to win approval, it would mark the first new therapy in more than 40 years for osteosarcoma, an aggressive bone cancer characterized by high rates of metastases, often to the lungs, and disease recurrence.<br /></div><a title="OS Therapies heading to FDA with positive osteosarcoma data" class="more" href="https://www.bioworld.com/articles/716293-os-therapies-heading-to-fda-with-positive-osteosarcoma-data">Read More</a> </div> </article> <article class="record article-summary "> <div class="article-summary__details "> <h2 class="headline article-summary__headline"><a href="https://www.bioworld.com/articles/716225-lillys-timely-25b-scorpion-deal-gsk-pays-1b-up-front-for-idrx">Lilly’s ‘timely’ $2.5B Scorpion deal; GSK pays $1B up front for Idrx</a></h2> <div class="post-meta"> <div class="date article-summary__post-date">Jan. 13, 2025</div> <div class="author article-summary__author">By <a href="/authors/3-jennifer-boggs">Jennifer Boggs</a></div> <div class="comment-count article-summary__comment-count"><a title="Lilly’s ‘timely’ $2.5B Scorpion deal; GSK pays $1B up front for Idrx" class="more" href="https://www.bioworld.com/articles/716225-lillys-timely-25b-scorpion-deal-gsk-pays-1b-up-front-for-idrx#comments-container">No Comments</a></div> </div> <div class="abstract article-summary__teaser">Joining the dealmaking spree to kick off the 2025 J.P. Morgan Healthcare Conference, Eli Lilly and Co. announced it was picking up an early clinical-stage PI3Kα inhibitor program from Scorpion Therapeutics Inc. in a deal that could be worth up to $2.5 billion, while GSK plc is adding to its cancer pipeline with the acquisition of Idrx Inc. for $1 billion up front.<br /></div><a title="Lilly’s ‘timely’ $2.5B Scorpion deal; GSK pays $1B up front for Idrx" class="more" href="https://www.bioworld.com/articles/716225-lillys-timely-25b-scorpion-deal-gsk-pays-1b-up-front-for-idrx">Read More</a> </div> </article> <article class="record article-summary "> <div class="image"><a title="Pfizer’s PD-1 inhibitor hits endpoint in BCG-naïve bladder cancer" class="url" rel="" target="" href="https://www.bioworld.com/articles/716166-pfizers-pd-1-inhibitor-hits-endpoint-in-bcg-naive-bladder-cancer"><img width="650" height="488" alt="Bladder cancer illustration" title="Bladder cancer illustration" border="0" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Bladder-cancer.png?height=488&t=1588882820&width=650" /></a></div> <div class="article-summary__details has-image"> <h2 class="headline article-summary__headline"><a href="https://www.bioworld.com/articles/716166-pfizers-pd-1-inhibitor-hits-endpoint-in-bcg-naive-bladder-cancer">Pfizer’s PD-1 inhibitor hits endpoint in BCG-naïve bladder cancer</a></h2> <div class="post-meta"> <div class="date article-summary__post-date">Jan. 10, 2025</div> <div class="author article-summary__author">By <a href="/authors/3-jennifer-boggs">Jennifer Boggs</a></div> <div class="comment-count article-summary__comment-count"><a title="Pfizer’s PD-1 inhibitor hits endpoint in BCG-naïve bladder cancer" class="more" href="https://www.bioworld.com/articles/716166-pfizers-pd-1-inhibitor-hits-endpoint-in-bcg-naive-bladder-cancer#comments-container">No Comments</a></div> </div> <div class="abstract article-summary__teaser">Though Pfizer Inc.’s work on a PD-1-targeting antibody has trailed far behind that of its fellow big pharmas, the company could be the first to market in treatment-naïve, high-risk non-muscle invasive bladder cancer on the back of solid phase III data showing subcutaneously administered sasanlimab hit its endpoint of event-free survival. Pfizer anticipates meeting with regulatory agencies to discuss potential filings for what could be the first new treatment for that NMIBC population in decades.<br /></div><a title="Pfizer’s PD-1 inhibitor hits endpoint in BCG-naïve bladder cancer" class="more" href="https://www.bioworld.com/articles/716166-pfizers-pd-1-inhibitor-hits-endpoint-in-bcg-naive-bladder-cancer">Read More</a> </div> </article> </div> <div class="see_all"><a class="next_page" rel="next" href="/authors/3-jennifer-boggs/articles?page=2">View All Articles by Jennifer Boggs</a></div> </div> </div></div> <aside class="main-interior-sidebar"><div class="main-interior-sidebar__column"><div id="article-recommendations"></div> </div><div class="main-interior-sidebar__column"><section class="popular-stories "> <h1 class="popular-stories__title">Popular Stories</h1><ul class="popular-stories__items"> <li class="popular-stories__item"> <article class="popular-stories__article popular-stories--article"><div class="popular-stories__details popular-stories__details-1"><h1 class="popular-stories__headline"><a class="popular-stories__article-title-link" href="https://www.bioworld.com/articles/432891-todays-news-in-brief">Today's news in brief</a></h1><div class="popular-stories__topics"><a class="popular-stories__topic-link" href="/topics/84-bioworld">BioWorld</a></div><div class="popular-stories__teaser"><em>BioWorld</em> briefs for Feb. 19, 2025.</div></div></article> </li> <li class="popular-stories__item"> <article class="popular-stories__article -has-image popular-stories--article"><figure class="popular-stories__image"><a class="popular-stories__thumbnail-link" data-eventname="popular-stories" data-eventcategory="click" data-eventaction="popular-stories-image" data-eventlabel="https://www.bioworld.com/articles/716835-european-vcs-optimistic-for-med-tech-exit-opportunities-in-2025" href="https://www.bioworld.com/articles/716835-european-vcs-optimistic-for-med-tech-exit-opportunities-in-2025"><img class="popular-stories__image-thumb" alt="Gold Euro symbol on blue background" title="Gold Euro symbol on blue background" width="640" height="355" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Money/Gold-Euro-on-blue-background.jpg?height=355&t=1729028866&width=640" /></a></figure><div class="popular-stories__details popular-stories__details-1"><h1 class="popular-stories__headline"><a class="popular-stories__article-title-link" href="https://www.bioworld.com/articles/716835-european-vcs-optimistic-for-med-tech-exit-opportunities-in-2025">European VCs optimistic for med-tech exit opportunities in 2025</a></h1><div class="popular-stories__topics"><a class="popular-stories__topic-link" href="/topics/85-bioworld-medtech">BioWorld MedTech</a></div><div class="popular-stories__teaser">To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...</div></div></article> </li> <li class="popular-stories__item"> <article class="popular-stories__article popular-stories--article"><div class="popular-stories__details popular-stories__details-1"><h1 class="popular-stories__headline"><a class="popular-stories__article-title-link" href="https://www.bioworld.com/articles/699574-todays-news-in-brief">Today's news in brief</a></h1><div class="popular-stories__topics"><a class="popular-stories__topic-link" href="/topics/85-bioworld-medtech">BioWorld MedTech</a></div><div class="popular-stories__teaser"><em>BioWorld MedTech</em> briefs for Feb. 19, 2025</div></div></article> </li> <li class="popular-stories__item"> <article class="popular-stories__article -has-image popular-stories--article"><figure class="popular-stories__image"><a class="popular-stories__thumbnail-link" data-eventname="popular-stories" data-eventcategory="click" data-eventaction="popular-stories-image" data-eventlabel="https://www.bioworld.com/articles/716928-european-vcs-bullish-on-med-tech-investments-in-2025" href="https://www.bioworld.com/articles/716928-european-vcs-bullish-on-med-tech-investments-in-2025"><img class="popular-stories__image-thumb" alt="White Euro symbol on blue background" title="White Euro symbol on blue background" width="640" height="355" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Money/Euro-currency-symbol-white.png?height=355&t=1669153720&width=640" /></a></figure><div class="popular-stories__details popular-stories__details-1"><h1 class="popular-stories__headline"><a class="popular-stories__article-title-link" href="https://www.bioworld.com/articles/716928-european-vcs-bullish-on-med-tech-investments-in-2025">European VCs bullish on med-tech investments in 2025</a></h1><div class="popular-stories__topics"><a class="popular-stories__topic-link" href="/topics/85-bioworld-medtech">BioWorld MedTech</a></div><div class="popular-stories__teaser">European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...</div></div></article> </li> <li class="popular-stories__item"> <article class="popular-stories__article -has-image popular-stories--article"><figure class="popular-stories__image"><a class="popular-stories__thumbnail-link" data-eventname="popular-stories" data-eventcategory="click" data-eventaction="popular-stories-image" data-eventlabel="https://www.bioworld.com/articles/717003-kura-kyowa-kirins-ziftomenib-hits-phase-ii-endpoints-in-aml" href="https://www.bioworld.com/articles/717003-kura-kyowa-kirins-ziftomenib-hits-phase-ii-endpoints-in-aml"><img class="popular-stories__image-thumb" alt="3D illustration of acute myeloid leukemia cells" title="3D illustration of acute myeloid leukemia cells" width="640" height="355" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/AML-Acute-Myekoid-Leukemia-Cells.jpg?height=355&t=1718812728&width=640" /></a></figure><div class="popular-stories__details popular-stories__details-1"><h1 class="popular-stories__headline"><a class="popular-stories__article-title-link" href="https://www.bioworld.com/articles/717003-kura-kyowa-kirins-ziftomenib-hits-phase-ii-endpoints-in-aml">Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML</a></h1><div class="popular-stories__topics"><a class="popular-stories__topic-link" href="/topics/84-bioworld">BioWorld</a></div><div class="popular-stories__teaser">Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...</div></div></article> </li> </ul> </section></div><div class="main-interior-sidebar__column"><div class="adplugg-tag" data-adplugg-zone="promo_1"></div></div></aside></div><footer class="main-footer"><div class="main-footer__top"><nav id="footer-1" class="main-footer__nav"><div class="navigation"><ul class="main-footer__nav-level1__items"><li class="main-footer__nav-level1__item"><a class="main-footer__nav__link -has-children" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="BioWorld|/topics/84-bioworld" href="/topics/84-bioworld">BioWorld</a><ul class="main-footer__nav-level2__items"><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Today's news|/topics/84-bioworld" href="/topics/84-bioworld">Today's news</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Analysis and data insight|/articles/topic/84,109-analysis-and-data-insight-bioworld" href="/articles/topic/84,109-analysis-and-data-insight-bioworld">Analysis and data insight</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Clinical|/articles/topic/84,153-clinical-bioworld" href="/articles/topic/84,153-clinical-bioworld">Clinical</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Data Snapshots|/snapshots" href="/snapshots">Data Snapshots</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Deals and M&A|/articles/topic/84,214-deals-bioworld" href="/articles/topic/84,214-deals-bioworld">Deals and M&A</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Financings|/articles/topic/84,292-financings-bioworld" href="/articles/topic/84,292-financings-bioworld">Financings</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Newco news|/articles/topic/84,391-newco-news-bioworld" href="/articles/topic/84,391-newco-news-bioworld">Newco news</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Opinion|/blogs/1-bioworld-perspectives" href="/blogs/1-bioworld-perspectives">Opinion</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Regulatory|/articles/topic/84,402-regulatory-bioworld" href="/articles/topic/84,402-regulatory-bioworld">Regulatory</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Science|/articles/topic/84,110-science-bioworld" href="/articles/topic/84,110-science-bioworld">Science</a></li></ul></li></ul></div></nav><nav id="footer-2" class="main-footer__nav"><div class="navigation"><ul class="main-footer__nav-level1__items"><li class="main-footer__nav-level1__item"><a class="main-footer__nav__link -has-children" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="BioWorld MedTech|/topics/85-bioworld-medtech" href="/topics/85-bioworld-medtech">BioWorld MedTech</a><ul class="main-footer__nav-level2__items"><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="Today's news|/topics/85-bioworld-medtech" href="/topics/85-bioworld-medtech">Today's news</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="Clinical|/articles/topic/85,153-clinical-bioworld-medtech" href="/articles/topic/85,153-clinical-bioworld-medtech">Clinical</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="Data Snapshots|/medtech_snapshots" href="/medtech_snapshots">Data Snapshots</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="Deals and M&A|/articles/topic/85,214-deals-bioworld-medtech" href="/articles/topic/85,214-deals-bioworld-medtech">Deals and M&A</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="Financings|/articles/topic/85,292-financings-bioworld-medtech" href="/articles/topic/85,292-financings-bioworld-medtech">Financings</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="Newco news|/articles/topic/85,391-newco-news-bioworld-medtech" href="/articles/topic/85,391-newco-news-bioworld-medtech">Newco news</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="Opinion|/blogs/2-bioworld-medtech-perspectives" href="/blogs/2-bioworld-medtech-perspectives">Opinion</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="Regulatory|/articles/topic/85,402-regulatory-bioworld-medtech" href="/articles/topic/85,402-regulatory-bioworld-medtech">Regulatory</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="Science|/articles/topic/85,110-science-bioworld-medtech" href="/articles/topic/85,110-science-bioworld-medtech">Science</a></li></ul></li></ul></div></nav><nav id="footer-3" class="main-footer__nav"><div class="navigation"><ul class="main-footer__nav-level1__items"><li class="main-footer__nav-level1__item"><a class="main-footer__nav__link -has-children" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="BioWorld Asia|/topics/86-bioworld-asia" href="/topics/86-bioworld-asia">BioWorld Asia</a><ul class="main-footer__nav-level2__items"><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="Today's news|/topics/86-bioworld-asia" href="/topics/86-bioworld-asia">Today's news</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="Analysis and data insight|/articles/topic/86,109-analysis-and-data-insight-bioworld-asia" href="/articles/topic/86,109-analysis-and-data-insight-bioworld-asia">Analysis and data insight</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="Australia|/articles/topic/86,394-australia-bioworld-asia" href="/articles/topic/86,394-australia-bioworld-asia">Australia</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="China|/articles/topic/86,395-china-bioworld-asia" href="/articles/topic/86,395-china-bioworld-asia">China</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="Clinical|/articles/topic/86,153-clinical-bioworld-asia" href="/articles/topic/86,153-clinical-bioworld-asia">Clinical</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="Deals and M&A|/articles/topic/86,214-deals-bioworld-asia" href="/articles/topic/86,214-deals-bioworld-asia">Deals and M&A</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="Financings|/articles/topic/86,292-financings-bioworld-asia" href="/articles/topic/86,292-financings-bioworld-asia">Financings</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="Newco news|/articles/topic/86,391-newco-news-bioworld-asia" href="/articles/topic/86,391-newco-news-bioworld-asia">Newco news</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="Regulatory|/articles/topic/86,402-regulatory-bioworld-asia" href="/articles/topic/86,402-regulatory-bioworld-asia">Regulatory</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="Science|/articles/topic/86,110-science-bioworld-asia" href="/articles/topic/86,110-science-bioworld-asia">Science</a></li></ul></li></ul></div></nav><nav id="footer-5" class="main-footer__nav"><div class="navigation"><ul class="main-footer__nav-level1__items"><li class="main-footer__nav-level1__item"><a class="main-footer__nav__link -has-children" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="BioWorld Science|/topics/520-bioworld-science" href="/topics/520-bioworld-science">BioWorld Science</a><ul class="main-footer__nav-level2__items"><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="Today's news|/topics/520-bioworld-science" href="/topics/520-bioworld-science">Today's news</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="Biomarkers|/articles/topic/520,543-biomarkers-bioworld-science" href="/articles/topic/520,543-biomarkers-bioworld-science">Biomarkers</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="Cancer|/articles/topic/520,239-cancer-bioworld-science" href="/articles/topic/520,239-cancer-bioworld-science">Cancer</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="Conferences|/articles/topic/520,154-conferences-bioworld-science" href="/articles/topic/520,154-conferences-bioworld-science">Conferences</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="Endocrine/Metabolic|/articles/topic/520,246-endocrine-metabolic-bioworld-science" href="/articles/topic/520,246-endocrine-metabolic-bioworld-science">Endocrine/Metabolic</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="Immune|/articles/topic/520,250-immune-bioworld-science" href="/articles/topic/520,250-immune-bioworld-science">Immune</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="Infection|/articles/topic/520,251-infection-bioworld-science" href="/articles/topic/520,251-infection-bioworld-science">Infection</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="Neurology/Psychiatric|/articles/topic/520,256-neurology-psychiatric-bioworld-science" href="/articles/topic/520,256-neurology-psychiatric-bioworld-science">Neurology/Psychiatric</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="Patents|/articles/topic/520,472-patents-bioworld-science" href="/articles/topic/520,472-patents-bioworld-science">Patents</a></li></ul></li></ul></div></nav><nav id="footer-4" class="main-footer__nav"><div class="navigation"><ul class="main-footer__nav-level1__items"><li class="main-footer__nav-level1__item"><a class="main-footer__nav__link -has-children" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="More|javascript:void(0);" href="javascript:void(0);">More</a><ul class="main-footer__nav-level2__items"><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="About|/about" href="/about">About</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Advertise with BioWorld|/advertising" href="/advertising">Advertise with BioWorld</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Archives|/newsletters" href="/newsletters">Archives</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Article reprints and permissions|/reprints" href="/reprints">Article reprints and permissions</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Contact us|https://clarivate.com/cortellis/contact-us/" target="_blank" href="https://clarivate.com/cortellis/contact-us/">Contact us</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Cookie policy|https://clarivate.com/legal/cookie-policy/" target="_blank" href="https://clarivate.com/legal/cookie-policy/">Cookie policy</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Copyright notice|https://clarivate.com/legal/copyright-notice/" target="_blank" href="https://clarivate.com/legal/copyright-notice/">Copyright notice</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Data methodology|/content/methodology-chart" href="/content/methodology-chart">Data methodology</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Infographics: Dynamic digital data analysis|/infographics-index" href="/infographics-index">Infographics: Dynamic digital data analysis</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Podcasts|/media/podcasts/532-bioworld-insider-podcast" href="/media/podcasts/532-bioworld-insider-podcast">Podcasts</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Privacy policy|https://clarivate.com/legal/privacy-policy/" target="_blank" href="https://clarivate.com/legal/privacy-policy/">Privacy policy</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Share your news with BioWorld|/share_your_news" href="/share_your_news">Share your news with BioWorld</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Staff|/staff" href="/staff">Staff</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Terms of use|https://clarivate.com/legal/terms-of-use/" target="_blank" href="https://clarivate.com/legal/terms-of-use/">Terms of use</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Topic alerts|/rss" href="/rss">Topic alerts</a></li></ul></li></ul></div></nav></div><div class="main-footer__bottom"><a class="social-media-links" title="Follow us" href="/social-media"><div class="social-media-links__callout">Follow Us</div><div class="social-media-links__twitter"></div> <div class="social-media-links__linkedin"></div></a></div><p class="main-footer__copyright">Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: <a href="http://www.epublishing.com" target="_blank">ePublishing</a><br /><button class="ot-sdk-show-settings" id="ot-sdk-btn" style="margin-top: 1rem">Cookie Settings</button></p></footer></div> <script async="async"> //<![CDATA[ require(['bundle/main.bundle']); //]]> </script> <script src="/javascripts/jquery.rating.pack.js?v=1740023123"></script> </body></html>